Moderna and Merck’s mRNA Cancer Vaccine Cuts Melanoma Recurrence by 49%

Moderna and Merck, known as MSD outside of the United States and Canada, recently revealed promising five-year data for their investigational cancer vaccine. They released a long-term analysis of the Phase 2b KEYNOTE-942 trial. This study targets patients with high-risk stage III or IV melanoma. Researchers treated patients who had undergone complete surgical resection. The regimen combined the mRNA therapy, intismeran autogene, with Merck’s Keytruda® (pembrolizumab). Results show this combination significantly outperforms Keytruda monotherapy. It successfully reduced the risk of recurrence or death by 49%.

Long-Term Efficacy: Sustained Protection for High-Risk Patients

The core of this announcement lies in the stability of the trial data. The first five years after surgery are critical for observing recurrence. Monitoring this window is vital for patient prognosis. The combination therapy showed sustained improvement in recurrence-free survival (RFS). This metric served as the trial’s primary endpoint. The data confirms a durable 49% reduction in risk compared to Keytruda alone. Statistical analysis yielded a significant p-value of 0.0075. Furthermore, both companies confirmed the safety profile remains consistent. No new safety signals emerged during this long-term follow-up.

Personalized mRNA Cancer Vaccine: Validating a New Oncology Modality

Intismeran autogene represents a breakthrough in Individualized Neoantigen Therapy (INT). Scientists design the vaccine based on a patient’s unique tumor mutations. This primes the immune system to specifically recognize and attack cancer cells. Moderna’s Senior Vice President and Head of Development, Oncology and Therapeutics, Kyle Holen, M.D., expressed strong confidence in these findings. He noted the durable benefit for high-risk melanoma patients. Holen emphasized that these results validate mRNA’s potential in oncology. Consequently, Moderna plans to continue aggressive investment in its oncology platform. They are currently advancing eight different clinical trials across various tumor types.

Addressing Unmet Needs in Post-Surgical Treatment

Merck’s senior vice president and head of oncology, global clinical development, Merck Research Laboratories, Marjorie Green highlighted the urgent clinical needs remaining in this field. She noted that recurrence risks persist significantly after surgery. This is particularly true for many stage III and IV melanoma patients. Proving a long-term reduction in recurrence is a meaningful clinical milestone. It demonstrates the potential of intismeran autogene combined with Keytruda. The companies aim to provide lasting benefits for specific melanoma populations. This partnership continues to explore new boundaries in immunotherapy.

From Melanoma to Multicancer: Moderna and Merck Scale Their Clinical Strategy

Following this success, Moderna and Merck are rapidly expanding their clinical footprint, aiming to replicate this model across other difficult-to-treat cancers. The Phase 3 melanoma trial, INTerpath-001, has completed patient enrollment. Focus has also shifted to non-small cell lung cancer (NSCLC), where two Phase 3 studies are currently recruiting. One evaluates adjuvant treatment following complete resection, while the other evaluates adjuvant treatment in patients with resectable NSCLC who have received prior neoadjuvant KEYTRUDA plus platinum-based chemotherapy.

Researchers are also targeting urologic cancers with similar intensity. A Phase 2 trial in renal cell carcinoma has completed enrollment, while studies in muscle-invasive and non-muscle-invasive bladder cancer are actively recruiting. Beyond the adjuvant setting, the companies are also exploring metastatic disease, including a Phase 2 first-line study in metastatic melanoma and another evaluating the therapy in metastatic squamous NSCLC.

Author

Steven Chung

紅杏枝頭春意鬧固然是眾人所追求的風景，但我願意說，青蘿拂行衣更能湧生感嘆。 願在海量晦澀的生醫資訊中，為您點亮一座心燈塔。鐘煌翔